One-Week Deadline Nears for Telix Investors in Securities Class Action
The case centers on allegations tied to an SEC probe and an FDA rejection that preceded steep share losses.
Overview
- January 9, 2026 is the cutoff for Telix shareholders to ask the court to be appointed lead plaintiff, with a class action already on file.
- The putative class covers purchases between February 21, 2025 and August 28, 2025.
- Notices say the complaints claim Telix overstated progress on prostate cancer therapeutics and the reliability of third-party supply and manufacturing partners.
- Filings highlight an SEC subpoena on development disclosures and an FDA Complete Response Letter rejecting Zircaix over CMC and Form 483 findings, after which shares fell sharply, including a 21% drop on the final news.
- Investor alerts emphasize that no class has been certified and that investors may pursue contingency-fee representation, with firms including Levi & Korsinsky, Rosen Law Firm, and Hagens Berman seeking participants.